Table 1 Baseline characteristics by sex in total cohort
Variables | Total (n = 857) | Male (n = 537) | Female (n = 320) | P value |
|---|---|---|---|---|
Age, years, Mean (SD) | 61.4 ± 10.2 | 59.5 ± 10.7 | 64.0 ± 8.9 | < 0.001 |
BMI, kg/m2, Mean (SD) | 25.3 ± 3.5 | 25.4 ± 3.4 | 24.5 ± 3.7 | 0.264 |
AF duration, m (IQR) | 12 (4–48) | 12 (4–48) | 12 (3.8–48) | 0.420 |
Type of AF, n (%) |  |  |  | < 0.001 |
 Paroxysmal | 476 (55.5) | 270 (50.3) | 206 (64.4) |  |
 Persistent | 381 (44.5) | 267 (49.7) | 114 (35.6) |  |
Concomitant medical history, n (%) | Â | Â | Â | Â |
 Hypertension | 384 (44.8) | 231 (43) | 153 (47.8) | 0.178 |
 Diabetes mellitus | 94 (11) | 53 (9.9) | 41(12.8) | 0.214 |
 History of stroke/TIA | 57 (6.7) | 39 (7.3) | 18 (5.6) | 0.397 |
 Chronic heart failure | 54 (6.3) | 37 (6.9) | 17 (2) | 0.387 |
 Coronary artery disease | 160 (18.7) | 97 (18.1) | 63 (19.7) | 0.587 |
AAD post-ablation, n (%) | 745 (86.9) | 468 (87.2) | 277 (86.6) | 0.805 |
Amiodarone, n (%) | 720 (84) | 453 (84.4) | 267 (83.4) | 0.722 |
propafenone, n (%) | 29 (3.4) | 18 (3.4) | 11 (3.4) | 0.947 |
LAD, mm, Mean (SD) | 36.6 ± 6.6 | 37.4 ± 6.4 | 35.3 ± 6.6 | < 0.001 |
LVEDD, mm, Mean (SD) | 48.3 ± 5.0 | 49.3 ± 5.0 | 46.4 ± 4.4 | < 0.001 |
LVEF, %, Mean (SD) | 55.9 ± 5.9 | 55.5 ± 6.5 | 56.5 ± 3.54.6 | 0.190 |
Ablation time, min (IQR) | 118 (90-161.5) | 118 (92–161) | 117.5 (88-163.8) | 0.711 |
LAV, ml (IQR) | 96 (76.9-118.9) | 99 (81-125.5) | 89.1 (73-109.9) | < 0.001 |
LAVI, ml /m2 (IQR) | 54 (43-66.6) | 53.8 (42.9–67.2) | 54.2 (43.7–65.3) | 0.936 |
extraPV ablation, n (%) | 144 (16.8) | 79 (14.7) | 65 (20.3) | 0.038 |
Follow-up, m (IQR) | 53 (37–72) | 51 (37–72) | 53 (37–72) | 0.606 |
ATa recurrence, n (%) | 303 (35.4) | 185 (34.5) | 118 (36.9) | 0.473 |